Proqr Therapeutics N.V. (PRQR) SEC Filings — 2024
18 SEC filings for Proqr Therapeutics N.V. (PRQR) in 2024.
Filings
- ProQR Therapeutics Secures $8.1M Funding — 6-K · Dec 11, 2024
- ProQR Therapeutics Appoints New CFO — 6-K · Dec 10, 2024
- ProQR Therapeutics Closes $100M Public Offering — 6-K · Dec 5, 2024
- ProQR Therapeutics Files 6-K for Q3 2024 — 6-K · Nov 7, 2024
- ProQR Therapeutics N.V. Enters Underwriting Agreement — 6-K · Oct 25, 2024
- ProQR Therapeutics Files 6-K Report — 6-K · Aug 8, 2024
- ProQR Therapeutics N.V. Holds 2024 Annual General Meeting — 6-K · May 22, 2024
- ProQR Therapeutics Files 6-K for Q1 2024 Results — 6-K · May 9, 2024
- ProQR Therapeutics Announces Preclinical Data for AX-0810 — 6-K · May 8, 2024
- ProQR Therapeutics Nominates Board Member, Sets Shareholder Meeting — 6-K · Apr 23, 2024
- ProQR Therapeutics Wins IP Challenge — 6-K · Apr 19, 2024
- ProQR Therapeutics Files 6-K, Announces Results — 6-K · Mar 13, 2024
- ProQR Therapeutics N.V. Files 20-F Annual Report for Fiscal Year 2023 — 20-F · Mar 13, 2024
- ProQR's Japanese Axiomer Patent Upheld After Opposition — 6-K · Feb 15, 2024
- Proqr Therapeutics N.V. SC 13G/A Filing — SC 13G/A · Feb 14, 2024
- Van Herk Investments Updates ProQR Therapeutics Stake — SC 13G/A · Feb 9, 2024
- ProQR Highlights New Axiomer™ RNA Editing Data at Deaminet 2024 — 6-K · Jan 19, 2024
- ProQR Partners with Rett Syndrome Research Trust on Axiomer™ RNA Editing — 6-K · Jan 5, 2024